Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Breast Cancer Research

Fig. 3

From: A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Fig. 3

Selective EGFR-TKIs erlotinib and gefitinib also synergise with PHA-767491 in TNBC. a Inhibitory impact of erlotinib and gefitinib on EGFR-mediated signal transduction in Hs578T and SKBR7 cells. b Dose response of Hs578T and SKBR7 cells to gefitinib or erlotinib (0.0316–3.16 μM) combined with 0.316, 1 or 3.16 μM PHA-767491. Data shown as mean ± standard deviation. Each graph shows one representative of two independent experiments performed in triplicate. Combination indices (CI) of gefitinib (3.16 μM) or erlotinib (3.16 μM) with PHA-767491 (1 μM or 3.16 μM) in Hs578T, BT549 and SKBR7 cells. d Initiation of DNA replication and productive transcriptional elongation in Hs578T cells treated with erlotinib or gefitinib and/or PHA-767491 as indicated, for 48 h. TKI refers to either erlotinib or gefitinib at 3.16 μM

Back to article page